Preparation and detailed characterization of the thiomer chitosan-cysteine as a suitable mucoadhesive excipient for nasal powders.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Oct 2022
Historique:
received: 14 07 2022
revised: 04 09 2022
accepted: 05 09 2022
pubmed: 12 9 2022
medline: 30 9 2022
entrez: 11 9 2022
Statut: ppublish

Résumé

The therapeutic application of nasal powders requires the development of novel mucoadhesive excipients. Thiolated polymers exhibit significant potential for this purpose based on their increased mucoadhesion attributable to the formation of disulfide bonds between the polymer and mucus surface. A chitosan-cysteine (chit-cyst) conjugate was synthesized using 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide in aqueous solution. The synthetic yield and synthesis conditions were optimized, and the efficiency of the reaction was evaluated. Rheological measurements revealed that the polymer derivative exhibited increased mucoadhesive properties in comparison to chitosan powder. To characterize the polymer, a novel purity investigation method was developed and verified to investigate the residual l-cysteine content. The results revealed that l-cysteine was not detectable in the resultant polymer matrix. Based on the cytotoxicity studies, chit-cyst was found to be safe for nasal application. Thereafter, nasal powder formulations were prepared using the polymer and the antiparkinsonian drug levodopa methyl ester hydrochloride by freeze-drying to investigate their nasal applicability. Based on the in vitro studies, these powders might be suitable for reducing the off periods of Parkinson's disease because of their expected higher in vivo mucoadhesion.

Identifiants

pubmed: 36089213
pii: S0378-5173(22)00742-6
doi: 10.1016/j.ijpharm.2022.122188
pii:
doi:

Substances chimiques

Antiparkinson Agents 0
Disulfides 0
Excipients 0
Polymers 0
Powders 0
Sulfhydryl Compounds 0
Chitosan 9012-76-4
Cysteine K848JZ4886

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122188

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Tamás Kiss (T)

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös str. 6, H-6720 Szeged, Hungary.

Rita Ambrus (R)

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös str. 6, H-6720 Szeged, Hungary.

Mohamed M Abdelghafour (MM)

Department of Physical Chemistry and Materials Science, University of Szeged, Rerrich Béla sqr. 1, H-6720 Szeged, Hungary; Department of Chemistry, Zagazig University, EG-44519 Zagazig, Egypt.

Scarlett Zeiringer (S)

Institute of Pharmaceutical Science, Department of Pharmaceutical Technology and Biopharmacy, University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.

Atiđa Selmani (A)

Institute of Pharmaceutical Science, Department of Pharmaceutical Technology and Biopharmacy, University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.

Eva Roblegg (E)

Institute of Pharmaceutical Science, Department of Pharmaceutical Technology and Biopharmacy, University of Graz, Universitätsplatz 1, A-8010 Graz, Austria.

Mária Budai-Szűcs (M)

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös str. 6, H-6720 Szeged, Hungary.

László Janovák (L)

Department of Physical Chemistry and Materials Science, University of Szeged, Rerrich Béla sqr. 1, H-6720 Szeged, Hungary.

Bálint Lőrinczi (B)

Institute of Pharmaceutical Chemistry, University of Szeged, Szeged, Eötvös str. 6, H-6720 Szeged, Hungary.

Ágota Deák (Á)

Department of Physical Chemistry and Materials Science, University of Szeged, Rerrich Béla sqr. 1, H-6720 Szeged, Hungary.

Andreas Bernkop-Schnürch (A)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-22, A-6020 Innsbruck, Austria.

Gábor Katona (G)

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös str. 6, H-6720 Szeged, Hungary. Electronic address: katona.gabor@szte.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH